60 results about "Antiparasite agent" patented technology

In particular this invention provides for spot-on compositions for the treatment or prophylaxis of parasite infestations in mammals or birds which comprise:

• • (1) a composition comprising
    • (A) an effective amount of a 1-phenylpyrazole derivative; and/or
    • (B) an effective amount of a macrocyclic lactone antihelmintic or antiparasitic agent;
  • (2) an acceptable liquid carrier vehicle; and
  • (3) optionally, a crystallization inhibitor.

The invention also provides for a method of treating parasitic infestations or for the prophylaxis of parasite infestations in mammals or birds which comprises topically applying to said mammal treating parasitic infestations or for the prophylaxis of parasite infestations in mammals or birds which comprises topically applying to said mammal or bird an effective amount of a composition according to the present invention.

The present invention provides methods for treating a coronavirus infection. For example, treatment may be effected by administering a neurotransmitter inhibitor, a signaling kinase inhibitor, an estrogen receptor inhibitor, a DNA metabolism inhibitor or an anti-parasitic agent. Also provided are methods for treating a coronavirus infection in which an anti-viral drug also is administered during any of the described methods.

Compounds of formula (I) are used in combination with a second antiparasitic agent for the treatment of parasitic infestations in a host animal.

Compounds of formula (I) are used in combination with a second antiparasitic agent for the treatment of parasitic infestations in a host animal.

Biologically-active, water soluble, 3-substituted trioxanes of the formula wherein R represents a COOH- substituted aryl group, a substituted or unsubstituted heteroaryl group or an alkyl group, and C12-(p-carboxy)benzyloxy trioxanes of formula wherein R represents a substituted or unsubstituted alkyl, alkenyl, aryl or heteroaryl group and methods for their use as antiparasitic agents, particularly for the treatment of malaria.

The present invention is directed to stabilized compositions comprising at least one macrocyclic lactone, or derivative thereof, in combination with levamisole, and an amino sugar stabilizing agent, optionally an additional antiparasitic agent, and a method for treating or controlling a parasitic infection or infestation in an animal by administering said composition.

Filarial parasites Brugia, Wuchereria, Loa Loa and Onchocerca cause over 20 million infections worldwide and pose a significant social and economic burden in endemic areas. The invention provides compositions and methods to treat parasitic infections in animals and plants, and to kill and inhibit the replication of parasites in infected hosts. The methods can include administering to a host in need of treatment an effective antiparasitic amount of a composition comprising biodegradable polyanhydride microparticles or nanoparticles that encapsulate antiparasitic agents, optionally in combination with antibacterial agents. Through co-encapsulation of antiparasitic and antibacterial agents into the particles, the invention provides the ability to effectively kill parasitic helminthes, worms, and flukes, with up to a 40-fold reduction in the amount of drug used. The results described herein demonstrate the effectiveness of the drug carriers to reduce both the course of treatment and the amount of drug needed to treat parasitic infections.

This invention provides a family of compounds that inhibit Class II fructose 1,6-bisphosphate aldolase (FBA), which is implicated in the pathogenic activity of a broad range of bacterial and parasitic agents. The compounds were identified by empirical testing, and provide a basis for further derivatization and optimization of 8-hydroxyquinoline-2-carboxylic acid and related compounds. Crystal structure shows that the compounds don't bind directly to the catalytic site of the enzyme, and so are not defined simply as substrate analogs. Instead, they create a pocket by induced fit, resulting a powerful and specific inhibitory effect on FBA activity.

A method for identifying antimicrobial agents comprises the steps of: (i) contacting a sample containing non-mammalian PPAT enzyme with a suitable substrate and a potential antimicrobial or antiprarasitic agent, under suitable conditions; (ii) measuring the activity of the PPAT enzyme; (iii) comparing the activity of the enzyme to that of a reference sample lacking the agent; and (iv) selecting an agent that reduces the activity of the PPAT enzyme.

An antiparasitic agent for fish containing an inhibitor of folate synthesis and/or an inhibitor of folate activation as the active substance(s). A combination preparation composed of an inhibitor of folate synthesis and an inhibitor of folate activation is preferable, and a sulfonamide is preferable for the inhibitor of folate synthesis. A dihydrofolate reductase inhibitor, a folate antagonist, etc., can be used as the inhibitor of folate activation.

The antiparasitic agent is able to exterminate fish parasites via oral administration. It is particularly effective against parasites belonging to the ciliate group among fish parasites.

The invention provides novel alkoxyaminochalcone derivatives and analogues thereof. Use of the compounds, or compositions comprising them, as pharmaceutically active agents, in particular against bacterial and parasitic infections, is also disclosed. The invention further relates to a method for detecting inhibitory effects against e.g., bacteria, parasites, fungi, and helminths. The chalcones of the invention carry amino substituents and exhibit enhanced biological effects combined with improved metabolic and physicochemical properties, making the compounds useful as drug substances, in particular as antiparasitic, bacteriostatic, and bacteriocidal agents.

Compositions and methods of use of borinic acid complexes, especially hydroxyquinoline, imidazole and picolinic acid derivatives as anti-parasitic agents as well as therapeutic agents for the treatment of diseases caused by parasite are described.

The subject matter of the present invention is the use of chitin or a derivative of chitin for preventing and/or treating parasitoses, and in particular cryptosporidiosis. The present invention also pertains to a composition that comprises at least one base agent chosen from among chitin or a derivative of chitin and at least one secondary agent chosen from among an agent for stimulating immunity and an antiparasite agent, as well as the use of same for preventing and/or treating parasitoses, in particular cryptosporidiosis.

The present invention relates to a new and efficient process for preparing 5-amino-1-(2,6-dichloro-4-(trifluo-romethyl)phenyl)-4-(trifluoromethylthio)-IH-pyrazole-3-carbonitrile (hereinafter referred to as compound of formula I), which is useful as an intermediate for the antiparasitic agent fipronil, and a process for preparing 5-amino-3-cyano-1-(2,6-dichloro-4-tri-fluoromethylphenyl)-4-trifluoromethyl sulfinylpyrazole (hereinafter referred to as compound of formula II or fipronil). In one aspect, there is provided a process for preparing fipronil comprising: a) a step of reacting CF₃S(═O)ONa with the compound of formula (III) in the presence of a reducing/halogenating agent; and b) a step of oxidizing the compound of formula (I) obtained in step a) in the presence of a selective oxidizing agent, under suitable conditions, wherein the selective oxidizing agent selectively effects oxidation of (I) to the corresponding sulfoxide, Fipronil. In certain exemplary embodiments, the selective oxidizing agent is MHSO₅, wherein M is an alkaline metal cation.

Diterpene dimer compounds 1-20, pharmaceutical compositions with the compounds as active components, and a preparation method thereof. The preparation method comprises the following steps: taking roots, rhizomes or tubers of lamiaceae plectranthus plants, performing direct cold leaching or thermal reflux extraction with an organic solvent of petroleum ether, n-hexane, chloroform, acetone, methanol, or ethanol, or firstly performing cold leaching or reflux extraction with the organic solvents, then performing extraction with ethyl acetate to obtain total extract, performing repeated chromatography of the total extract to obtain the compounds of the invention. Pharmaceutical compositions with the compounds of the invention as active components can be used for resisting tumor and parasitic diseases. An application of the compounds of the invention in preparation of antitumor agents and anti-parasitic agents comprises: applying the compounds with an amount of 1.6-200 microgram/mL to a substrate or a population, and optionally bonding with carriers and/or media to obtain good cytotoxic activity; applying the compounds with an amount of 0.4-277.8 microgram/mL to a substrate or a population, and optionally bonding with carriers and/or media to obtain good anti-parasitic activity.

The present invention relates to a method for preparing a cyclic peptide with antiparasite activity and anticancer activity. The invention also relates to this peptide as an antiparasite agent, for example in the treatment of toxoplasmosis and as an anticancer agent. The invention also relates to the use of this cyclic peptide for treating organs ex vivo before transplantation.

The invention recites spirocyclic derivatives of Formula (V.1) or (V.2), stereoisomers thereof, veterinary acceptable salts thereof, compositions thereof, processes for making, and their use as a parasiticide for an animal. The variables A, B, V, Z, Y, W1, W2, W3, R1a, R1b, R1c, R2, R3, R4, n, and "---" are as described herein.

The invention recites spirocyclic isoxazoline derivatives of Formula (1) stereoisomers thereof, veterinary or pharmaceutical acceptable salts thereof, compositions thereof, processes for making, and their use as a parasiticide in an animal. The variables W1, W2, W3, W, X, R1a, R1b, R1c, R2, R3, R4, and n are as described herein.

A method of controlling proliferation of fish parasites comprising the administration of 1 to 50 mg/kg fish body weight/day of an inhibitor of folate synthesis and/or an inhibitor of folate activation to fish continuously for 1 to 2 weeks. Using a combination preparation composed of an inhibitor of folate synthesis and an inhibitor of folate activation is preferable, and a sulfonamide is preferable for the inhibitor of folate synthesis. A dihydrofolate reductase inhibitor, a folate antagonist, etc., can be used as the inhibitor of folate activation. The antiparasitic agent is able to exterminate fish parasites via oral administration. It is particularly effective against parasites belonging to the ciliate group among fish parasites.